Levosimendán Carinopharm

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendán Carinopharm (Levosimendan)

Q: What is Levosimendán Carinopharm used for?

Levosimendán Carinopharm is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure in hospitalized patients. It improves cardiac contractility and reduces vascular resistance, helping to restore adequate cardiac output during severe low‑output states.

Q: How does levosimendan work?

Levosimendan binds to troponin C in cardiac muscle, increasing its sensitivity to calcium and thereby enhancing contractile force without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation, which lowers preload and afterload.

Q: What is the usual dose of levosimendan?

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. The product is supplied as an injectable solution for intravenous infusion, and the prescriber sets the infusion rate and duration.

Q: Is levosimendan safe during pregnancy or breastfeeding?

The safety of levosimendan in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

Q: How do I order Levosimendán Carinopharm from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Q: How does levosimendan compare with other inotropic agents?

Unlike traditional catecholamine inotropes, levosimendan increases contractility by sensitizing troponin C to calcium rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel opening, offering combined inotropic and afterload‑reducing effects.

Q: What are the storage and handling requirements for Levosimendán Carinopharm?

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Q: How is Levosimendán Carinopharm administered?

Levosimendán Carinopharm is given as an intravenous infusion. After reconstitution, the solution is administered through a controlled infusion pump, typically starting with a loading dose followed by a maintenance infusion, under continuous cardiac and hemodynamic monitoring.

Q: What are the most serious risks associated with levosimendan?

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Patients should be monitored closely for blood pressure changes, ECG abnormalities, and signs of allergic response throughout the infusion.

Q: Who should not receive levosimendan?

Levosimendan is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in patients with significant renal or hepatic impairment.

Levosimendan, the active ingredient in Levosimendán Carinopharm, is a calcium sensitizer presented as an injection solution for intravenous use. It treats acute decompensated heart failure in hospitalized adults.
GNH India supplies Levosimendán Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Carinopharm Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan acts on the cardiovascular system to improve cardiac performance in severe heart failure conditions.
Acute decompensated heart failure: improves cardiac output and relieves symptoms of low‑output state.
Cardiogenic shock (off‑label): provides inotropic support when conventional agents are insufficient.
Post‑cardiac surgery low‑output syndrome: helps maintain hemodynamic stability after major cardiac procedures.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation, which reduces cardiac preload and afterload.

Side Effects

Levosimendan may cause several adverse reactions during treatment.

Common Side Effects

Hypotension: drop in blood pressure, especially during initial infusion.
Headache: mild to moderate intensity.
Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects

Ventricular arrhythmias: potentially life‑threatening heart rhythm disturbances.
Severe hypotension: marked blood pressure fall requiring intervention.
Myocardial ischemia: reduced blood flow to heart muscle.
Allergic reactions: rash, itching, or anaphylaxis.
Pulmonary edema: fluid accumulation in lungs.
Elevated liver enzymes: indication of hepatic stress.

Precautions & Warnings

Levosimendan requires careful monitoring in clinical settings.

Cardiac monitoring: continuous ECG and hemodynamic assessment.
Blood pressure monitoring: frequent checks to detect hypotension.
Electrolyte balance: correct potassium and magnesium levels before infusion.
Renal function: evaluate creatinine clearance, especially in patients with renal impairment.
Contraindicated in severe hypotension: avoid use when systolic BP < 90 mmHg.
Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents.

Major Interactions (Avoid)

Potent vasodilators (e.g., nitroprusside): may cause severe hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase levosimendan plasma concentrations.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt the inotropic response.
Diuretics: can exacerbate volume depletion and hypotension.
Calcium channel blockers: may affect vascular tone and blood pressure.

Frequently Asked Questions

Levosimendán Carinopharm is an intravenous calcium sensitizer indicated for the treatment of acute decompensated heart failure in hospitalized patients. It improves cardiac contractility and reduces vascular resistance, helping to restore adequate cardiac output during severe low‑output states.

Levosimendan binds to troponin C in cardiac muscle, increasing its sensitivity to calcium and thereby enhancing contractile force without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation, which lowers preload and afterload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. The product is supplied as an injectable solution for intravenous infusion, and the prescriber sets the infusion rate and duration.

The safety of levosimendan in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility by sensitizing troponin C to calcium rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel opening, offering combined inotropic and afterload‑reducing effects.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Levosimendán Carinopharm is given as an intravenous infusion. After reconstitution, the solution is administered through a controlled infusion pump, typically starting with a loading dose followed by a maintenance infusion, under continuous cardiac and hemodynamic monitoring.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Patients should be monitored closely for blood pressure changes, ECG abnormalities, and signs of allergic response throughout the infusion.

Levosimendan is contraindicated in patients with severe hypotension (systolic BP < 90 mmHg), uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in patients with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.